Brink Biologics Inc. v. Sanofi S.A.

Good Law
United States District Court, Central District of CaliforniaApril 19, 20212:21-cv-02171California1,969 words

Opinion

trial_court Opinion

CENTRAL DISTRICT OF CALIFORNIA

CIVIL MINUTES - GENERAL

Case No. CV 21-2171 FMO (Ex) Date April 19, 2021 Title Brink Biologics, Inc. v. Sanofi S.A., et al.

Present: The Honorable Fernando M. Olguin, United States District Judge Vanessa Figueroa None None Deputy Clerk Court Reporter / Recorder Tape No. Attorney Present for Plaintiff(s): Attorney Present for Defendant(s): None Present None Present Proceedings: (In Chambers) Order Remanding Action On January 19, 2021, plaintiff Brink Biologics, Inc. (“plaintiff”) filed a Complaint in the Los Angeles County Superior Court against Sanofi S.A., Sanofi-Aventis US LLC (“Sanofi US”), and Sanofi-Aventis Recherche & Developpement S.A. (collectively, “defendants”), asserting claims for breach of contract, declaratory relief, restitution for unjust enrichment, and violations of California’s Unfair Competition Law (“UCL”), Cal. Bus. & Prof. Code §§ 17200, et seq. (See Dkt. 1, Notice of Removal (“NOR”) at 1); (Dkt. 1-2, Exh. 1, Complaint at ¶¶ 52-85). On March 10, 2021, Sanofi US removed the action on diversity jurisdiction grounds pursuant to 28…

Sign in to read the full opinion

Create a free account to read the complete opinion text, citation history, and good-law status for this case.